about
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.New agents for intrathecal administration.Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.Current therapy and future prospects in lymphoma.Mantle cell lymphoma: a biological and therapeutic paradigm.Current trends in large cell lymphoma.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab VedotinBendamustine in the treatment of non-Hodgkin's lymphomas.Treatment of the elderly patient with diffuse large B cell lymphoma.Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry.Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.Debulking surgery for patients with diffuse large B-cell non-Hodgkin's lymphoma.Velcade combinations in mantle cell lymphoma: are we learning anything?
P2860
Q33337520-81234675-B4B4-4CC9-8466-1FFD8A14FC46Q33347071-9155CA90-54F7-4F97-A925-3F8340A98402Q33364319-7E941935-4334-4C84-A751-93164BDDE435Q33365711-0A5A7077-F68A-481D-ABE0-4F41D34C2775Q33383608-70E1F3A7-3C0B-4376-83B9-70390A7E5509Q33394153-498594D5-A029-4F1B-822A-230CE837D5CCQ33396261-8FAF5944-2A74-408C-AF5F-F6398721A08EQ33409608-C263CD9B-5525-4A0A-A3FE-EC18D1025118Q33431457-A0E45CCF-53DD-4619-A5AC-C6204D12F5B2Q33999083-1BDD1C36-508C-4FD6-B4EF-E96DC5C7CB84Q34185007-B094CBC9-9006-4424-9838-A2626B116162Q34734296-B2544E79-5186-417B-96DE-0DA35547B57DQ34769876-8026348C-6235-4066-A5AD-4F6C54CF9D60Q35545076-7500740D-19DB-44AF-A07F-B7A29A6F2976Q35669134-787FD962-909E-4CDF-B429-F9A813429C70Q37771253-70F613B2-AF33-4148-AE66-2BB991F3D466Q37998553-2DD60C9E-FE1D-47D5-A584-1FE16DD0073BQ38768797-06711D4E-896D-41D4-A7A8-A5EDF15DB323Q43814680-8C971392-8D72-436F-B5B8-EFFF56BE6E40Q45141158-78470231-F507-4346-AAFD-2B220059A07EQ46882254-822ACA70-2DE9-4BA0-88A3-DCCB17C5404EQ46909218-76203D53-91AD-4061-8DAA-D8D72F61D31BQ51654977-1DDE0EF0-3EB3-4899-8D25-91158052FCF3Q51876606-7BD80F9A-749E-4483-A461-D92DCA9687A7
P2860
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Gemcitabine for relapsed or resistant lymphoma.
@en
Gemcitabine for relapsed or resistant lymphoma.
@nl
type
label
Gemcitabine for relapsed or resistant lymphoma.
@en
Gemcitabine for relapsed or resistant lymphoma.
@nl
prefLabel
Gemcitabine for relapsed or resistant lymphoma.
@en
Gemcitabine for relapsed or resistant lymphoma.
@nl
P2093
P356
P1433
P1476
Gemcitabine for relapsed or resistant lymphoma.
@en
P2093
D G Savage
M L Keohan
S A Johnson
P304
P356
10.1023/A:1008307528519
P577
2000-05-01T00:00:00Z